DoD Tuberous Sclerosis Complex, Idea Development Award
ID: 353645Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353645
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 19, 2024, 12:00 AM UTC
  4. 4
    Due Aug 1, 2024, 12:00 AM UTC
Description

The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Tuberous Sclerosis Complex (TSC) Idea Development Award, a federal grant aimed at supporting innovative research that addresses high-impact findings in TSC. This opportunity encourages applications that propose conceptually innovative research with a strong scientific rationale and preliminary data, focusing on areas such as neuropsychiatric disorders, tumor prevention, and epilepsy treatments associated with TSC. With an estimated total program funding of $2.4 million and the expectation of awarding three grants, the application process includes a pre-application due by June 12, 2024, followed by a full application due by August 1, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

Point(s) of Contact
help@eBRAP.org
Files
Title
Posted
HT942524TSCRPIDA_GG.pdf
Aug 24, 2024, 2:22 AM UTC
The Department of Defense's FY24 Tuberous Sclerosis Complex Research Program seeks applications for the Idea Development Award aimed at high-impact research relevant to Service Members, Veterans, and the public. The application process involves a two-step submission, starting with a pre-application due by June 12, 2024, followed by a full application due by August 1, 2024. This funding opportunity, with $8 million appropriated for FY24, emphasizes research that innovatively addresses areas like neuropsychiatric disorders associated with Tuberous Sclerosis Complex (TSC), tumor prevention, and epilepsy treatments. Eligible applicants include independent investigators, both established and those new to TSC research, with a budget cap of $500,000 for a maximum performance period of three years. The review process is two-tiered, involving peer and programmatic assessments, with a focus on impact, innovation, and feasibility of the proposed studies. The announcement outlines strict submission guidelines and eligibility criteria to ensure compliance with funding regulations while promoting advancements in TSC research.
Similar Opportunities
NFRP Outreach and Invitation for Response
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
Dept. of the Army -- USAMRAA
The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities
USAF 347 Contracting Squadron
The USAF 347 Contracting Squadron is offering a federal grant opportunity titled "US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities." This initiative aims to foster the discovery, development, and integration of novel science and technologies specifically within the Indo-Pacific region, explicitly excluding engagements in the Continental United States. The funding, categorized under Science and Technology and other Research and Development, has an award ceiling of $9.5 million and a floor of $10,000, with an expected 51 awards to be made. Interested applicants can reach out to Mr. Kazuhito Urano or Mr. Joshua B. Grubb for further inquiries, and proposals must be submitted by August 30, 2027, as detailed on the System for Award Management (SAM) website.
Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators, a federal grant aimed at fostering innovative biomedical research that integrates engineering with life sciences. This funding opportunity, under the R21 Exploratory/Developmental Research Grant mechanism, allows for up to $400,000 in direct costs over a three-year period for projects that require minimal preliminary data, encouraging high-risk, high-reward research. The initiative is designed to enhance diversity within the research community and is open to a wide range of eligible applicants, including various educational institutions and community organizations. Interested parties should note that the application submission period opens on January 16, 2025, and closes on January 8, 2026; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This initiative aims to support the development of innovative technologies that address barriers in therapeutic development, specifically targeting high-risk, high-reward projects that are in the early stages of proof-of-concept. The program is particularly significant as it seeks to enhance the efficiency of the therapeutic development pipeline, ultimately leading to faster delivery of treatments to patients. Grants of up to $275,000 are available over a two-year period, with applications accepted starting May 19, 2025, and a submission deadline of June 19, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Military and Civilian Partnership for Trauma Readiness Grant Program/Mission Zero
Admin for Strategic Preparedness and Response
The Administration for Strategic Preparedness and Response is offering the Military and Civilian Partnership for Trauma Readiness Grant Program, also known as the Mission Zero Act, to support high-acuity trauma centers in enhancing military-civilian partnerships for improved trauma care. This grant program aims to award up to 30 eligible trauma centers, enabling military trauma teams to provide full-time trauma and acute care services, thereby strengthening the nation's response to public health and medical emergencies. With an estimated total program funding of $4 million and an award ceiling of $4 million per grant, interested applicants, including nonprofits without 501(c)(3) status and hospitals, should note that the application period is expected to open on January 15, 2025, with a closing date of April 14, 2025. For further inquiries, applicants can contact Leslie Beck at 301-346-4857 or via email at leslie.beck@hhs.gov.
Autism Research Consortium (Autism RC)
Health Resources and Services Administration
The Health Resources and Services Administration (HRSA) is inviting applications for the Autism Research Consortium (Autism RC), aimed at supporting research that enhances the health and well-being of children and adolescents with autism. This initiative seeks to fund up to five research centers with a total budget of $5 million, providing cooperative agreements valued at up to $1 million per year for three years, focusing on innovative interventions and systems that address disparities in care. The program emphasizes the importance of partnerships with affected communities to develop evidence-based practices that improve physical and behavioral health outcomes for autistic children and their families. Applications are due by April 23, 2025, and interested parties can contact Deborah Quint Shelef and Emmie Perchak at autismrc@hrsa.gov for further information.
Department of Defense Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI)
Dept of the Army -- Materiel Command
The Department of the Army's Materiel Command is offering a federal grant opportunity through the Department of Defense Research and Education Program aimed at Historically Black Colleges and Universities and Minority-Serving Institutions (HBCUs/MIs). This initiative seeks to enhance defense-related research and educational capabilities at these institutions, with a focus on increasing the number of graduates in STEM disciplines and fostering collaborations with other educational institutions and defense organizations. The program is critical for addressing national defense research priorities and strengthening the defense workforce through educational enhancements. Eligible applicants can apply for grants ranging from $100 million, with applications due by July 31, 2029. For further inquiries, interested parties can contact William A. Creech at william.a.creech3.civ@army.mil or by phone at 919-549-4387.
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.